Institute of Medicinal Plant Development, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, 100193, China; Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, 100193, China.
Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
J Ethnopharmacol. 2021 Apr 6;269:113708. doi: 10.1016/j.jep.2020.113708. Epub 2020 Dec 24.
Paeonia, which comprises approximately 52 shrubs or herbaceous perennials around the world, is the only genus of the Paeoniaceae and is pervasively distributed in Asia, southern Europe, and North America. Many species of the genus Paeonia have been used for centuries in ethnomedical medical systems.
The present study aims to summarize the traditional uses, clinical applications, and toxicology of the genus Paeonia, to critically evaluate the state-of-the-art phytochemical and pharmacological studies of this genus published between 2011 and 2020, and to suggest directions for further in-depth research on Paeonia medicinal resources.
Popular and widely used databases such as PubMed, Scopus, Science Direct, and Google Scholar were searched using the various search strings; from these searches, a number of citations related to the traditional uses, phytochemistry, biological activities, clinical application, and toxicology of the genus Paeonia were retrieved.
The use of 21 species, 2 subspecies, and 7 varieties of the genus Paeonia as traditional herbal remedies has been reported, and many ethnomedicinal uses, such as the treatment of hematemesis, blood stasis, dysmenorrhea, amenorrhea, epilepsy, spasms, and gastritis, have been recorded. The roots and root bark are the most frequently reported parts of the plants used in medicinal applications. In phytochemical investigations, 451 compounds have been isolated from Paeonia plants to date, which contains monoterpenoid glucosides, flavonoids, tannins, stilbenes, triterpenoids and steroids, and phenols. Studies of their pharmacological activities have revealed the antioxidant, anti-inflammatory, antitumour, antibacterial, antiviral, cardiovascular protective, and neuroprotective properties of the genus Paeonia. In particular, some bioactive extracts and compounds (total glucosides of peony (TGP), paeonol, and paeoniflorin) have been used as therapeutic drugs or tested in clinical trials. In addition to the "incompatibility" of the combined use of "shaoyao" and Veratrum nigrum L. roots in traditional Chinese medicine theory, Paeonia was considered to have no obvious toxicity based on the available toxicological tests.
A large number of phytochemical and pharmacological reports have indicated that Paeonia is an important medicinal herb resource, and some of its traditional uses including the treatment of inflammation and cardiovascular diseases and its use as a neuroprotective agent, have been partially confirmed through modern pharmacological studies. Monoterpenoid glucosides are the main active constituents. Although many compounds have been isolated from Paeonia plants, the biological activities of only a few of these compounds (paeoniflorin, paeonol, and TGP) have been extensively investigated. Some paeoniflorin structural analogues and resveratrol oligomers have been preliminarily studied. With the exception of several species (P. suffruticosa, P. ostii, P. lactiflora, and P. emodi) that are commonly used in folk medicine, many medicinal species within the genus do not receive adequate attention. Conducting phytochemical and pharmacological experiments on these species can provide new clues that may lead to the discovery of medicinal resources. It is necessary to identify the effective phytoconstituents of crude extracts of Paeonia that displayed pharmacological activities by bioactivity-guided isolation. In addition, comprehensive plant quality control, and toxicology and pharmacokinetic studies are needed in the future studies.
芍药属约有 52 种灌木或草本植物分布于世界各地,是毛茛科唯一的属,广泛分布于亚洲、南欧和北美。该属的许多种植物在几个世纪以来一直被用于民族医学系统。
本研究旨在总结芍药属植物的传统用途、临床应用和毒理学,批判性地评估 2011 年至 2020 年间发表的关于该属植物的植物化学和药理学研究的最新进展,并提出进一步深入研究芍药药用资源的方向。
使用各种搜索字符串在 PubMed、Scopus、Science Direct 和 Google Scholar 等流行和广泛使用的数据库中进行搜索,从这些搜索中检索到与芍药属植物的传统用途、植物化学、生物活性、临床应用和毒理学相关的许多引用。
报告了 21 种、2 个亚种和 7 个变种的芍药属植物作为传统草药的用途,记录了许多民间药用用途,如治疗吐血、血瘀、痛经、闭经、癫痫、痉挛和胃炎。植物的根和根皮是药用应用中最常报道的部分。在植物化学研究中,迄今为止已从芍药属植物中分离出 451 种化合物,其中包含单萜苷、类黄酮、单宁、芪类、三萜和甾体以及酚类化合物。对其药理活性的研究表明,芍药属植物具有抗氧化、抗炎、抗肿瘤、抗菌、抗病毒、心血管保护和神经保护作用。特别是一些生物活性提取物和化合物(丹皮总苷(TGP)、丹皮酚和芍药苷)已被用作治疗药物或在临床试验中进行测试。除了中药理论中“芍药”和藜芦根合用的“相恶”外,根据现有的毒理学试验,芍药被认为没有明显的毒性。
大量的植物化学和药理学报道表明,芍药是一种重要的药用植物资源,其一些传统用途,包括治疗炎症和心血管疾病以及作为神经保护剂,已经部分通过现代药理学研究得到证实。单萜苷是主要的活性成分。虽然从芍药植物中分离出了许多化合物,但只有少数化合物(芍药苷、丹皮酚和 TGP)的生物活性得到了广泛研究。一些芍药苷结构类似物和白藜芦醇低聚物已初步研究。除了几种(牡丹、川赤芍、芍药和赤芍)在民间医学中常用的物种外,该属的许多药用物种都没有得到足够的关注。对这些物种进行植物化学和药理学实验可以提供新的线索,可能导致发现药用资源。有必要通过生物活性导向分离来鉴定显示药理活性的芍药粗提取物的有效植物成分。此外,未来的研究还需要进行全面的植物质量控制、毒理学和药代动力学研究。